|1.||Jablonowski, D: 2 articles (09/2002 - 11/2001)|
|2.||Schaffrath, R: 2 articles (09/2002 - 11/2001)|
|3.||Schaffrath, Raffael: 2 articles (07/2002 - 05/2002)|
|4.||Kitamoto, H K: 1 article (09/2002)|
|5.||Nagase, J: 1 article (09/2002)|
|6.||Jablonowski, Daniel: 1 article (07/2002)|
|7.||Fichtner, Lars: 1 article (05/2002)|
|8.||Fichtner, L: 1 article (11/2001)|
|9.||Stark, M J: 1 article (11/2001)|
|10.||Frohloff, F: 1 article (11/2001)|
09/01/2002 - "The defects at the level of transcriptional elongation displayed by rtf1Delta, ctk1, fcp1 and rpb2 mutants also result in zymocin hypersensitivity. "
05/01/2002 - "Disruption of KTI11 and KTI13 results in the complex tot phenotype observed for the gamma-toxin target site mutants, tot1-7, and includes zymocin resistance, thermosensitivity, hypersensitivity to drugs and slow growth. "
11/01/2001 - "Deletions of both TOT6 and TOT7 result in the complex tot phenotype, including resistance to zymocin, thermosensitivity, slow growth and hypersensitivity towards drugs, thus reinforcing the notion that TOT/Elongator may be crucial in signalling zymocicity. "
09/01/2002 - "In a study of zymocin's mode of action, genetic scenarios known to impair transcription or affect the pol II machinery itself were found to elicit hypersensitivity to zymocin. "
09/01/2002 - "Defects in yeast RNA polymerase II transcription elicit hypersensitivity to G1 arrest induced by Kluyveromyces lactis zymocin."
|1.||DNA Polymerase II
|2.||RNA Polymerase II (RNA Polymerase B)
|3.||carboxy-terminal domain kinase